New Zealand decision follows Australian approval in 2023 of psychedelics to treat PTSD and treatment-resistant depression
Two psychiatrists in New Zealand won approval on Friday to prescribe pharmaceutical-grade MDMA to people with severe post-traumatic stress disorder (PTSD).
The move by New Zealand’s pharmaceutical regulatory body Medsafe makes the country only the second worldwide to approve the party drug for use in treating PTSD, following Australia in 2023.
